Highlighting Commercial Validation of Immune Reset Through Allogeneic Cell Therapy & Expanding Into Autoimmune Disease
9:30 am - Wednesday 2nd December 2026
- Examining the FDA approval of Orca-T and what this milestone signals for regulatory acceptance of next-generation allogeneic immune reset therapies
- Demonstrating how this transplant-replacement platform significantly reduces toxicity while preserving the curative potential of allogeneic hematopoietic stem cell transplantation
- Showcasing Orca-Q as the next-generation platform being advanced toward autoimmune disease, translating lessons from hematologic malignancies into severe autoimmune indications
